Table 3

Never-smokers at the most recent assessment*: fixed-effect meta-analysis results on model 3 (adjusted for age, sex, smoking, education and season of interview) for all air pollutants and traffic indicators for each outcome, using ESCAPE-period (2008–2011) exposures from all five cohorts

OutcomeChronic bronchitisChronic coughChronic phlegm
Exposure‡ORphet§ORphetORphet
(95% CI)(95% CI)(95% CI)
PM2.5 (5 µg/m3)1.280.4881.110.0911.160.519
(0.95 to 1.72)(0.90 to 1.36)(0.91 to 1.48)
PM2.5abs (per 10−5 m−1)1.200.2331.160.0321.100.602
(0.92 to 1.57)(0.96 to 1.39)(0.87 to 1.39)
1.27† (0.88 to 1.85)
PM10 (10 µg/m3)1.350.7631.080.5351.320.474
(0.97 to 1.88)(0.86 to 1.35)(1.02 to 1.71)
PMcoarse (5 µg/m3)1.150.9791.060.9541.310.457
(0.87 to 1.53)(0.87 to 1.29)(1.05 to 1.64)
NO2 (10 µg/m3)1.060.4401.040.0881.020.234
(0.93 to 1.20)(0.97 to 1.12)(0.92 to 1.13)
NOx (20 µg/m3)1.090.1511.040.0211.050.121
(0.93 to 1.28)(0.97 to 1.12)(0.96 to 1.15)
1.06† (0.91 to 1.23)
Traffic intensity¶1.120.7631.070.6291.040.830
(0.79 to 1.57)(0.84 to 1.37)(0.80 to 1.37)
Traffic load**1.110.3541.030.511.020.422
(0.83 to 1.49)(0.82 to 1.29)(0.79 to 1.32)
  • Bold type denotes statistical significance, p <0.05. *Asthma-E3N 2011, ECRHS 1998–2002, NSHD 2008, SALIA 2006–10, SAPALDIA 2002. Due to questionnaire wording SALIA (>70% never-smokers) is not included in analyses of phlegm alone.

  • †Estimates from random-effect meta-analysis as Phet: <0.05.

  • ‡Results were interpreted as per exposure unit, as shown in the parentheses.

  • §Phet: P-value for heterogeneity.

  • ¶Binary variable, <5000 (reference group) vs >5000 vehs/day.

  • **Binary variable, <500 000 (reference group) vs >500 000 vehs m/day.

  • ECRHS, European Community Respiratory Health Survey; ESCAPE, European Study of Cohorts for Air Pollution Effects; NOx; nitrogen oxides; NSHD, National Survey of Health and Development; PM, particulate matter; SALIA, Study on the influence of Air pollution on Lung function, Inflammation and Aging; SAPALDIA, Swiss cohort study on Air Pollution And Lung and heart Diseases in Adults.